Online citations, reference lists, and bibliographies.
← Back to Search

Recent And Future Therapeutic Advances In The Management Of HIV Infection.

G. Saliba, P. Yeni
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Human immunodeficiency virus (HIV) infection is a worldwide pandemic that remains a major health and socio-epidemiological problem at the beginning of the 21st century, including in developed countries. In 2006, 10 years after the introduction of highly active antiretroviral therapy (HAART), therapeutic needs in HIV are different from what they were a decade ago. Physicians now handle more than 20 different molecules, all active against HIV virus. However, they still need safe, tolerable and simple regimens in order to improve patient's compliance to therapy, as well as more potent drugs in cases of multi-resistant viral strains. Our understanding of HIV infection and its medical management has improved and will certainly continue to evolve. We are currently taking benefit from the elaboration and evaluation of various new therapeutic concepts and promising future medical approaches based on already 20 years experience in the field of HIV management, as well as on the rapidly expanding pharmaceutical development and researches in this domain. Nevertheless, the majority of these new therapeutic strategies are still to be further evaluated, and their practical application is awaiting the results of numerous ongoing clinical trials.
This paper references
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
R. Gulick (2004)
XV International AIDS Conference in Bangkok: antiretroviral therapy.
Gallant Je (2004)
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
A. D. Monforte (2000)
Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression: 48-Week Results of a Randomized, Controlled, Open-Label, Proof-of-Concept Pilot Clinical Trial (OK Study)
J. Arribas (2005)
Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV
K. Squires (2004)
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
S. Bozzette (2003)
Treatment of HIV/AIDS: do the dilemmas only increase?
M. Sande (2004)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
S. Hammer (2006)
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
J. Gallant (2004)
Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients
E. Dejesus (2006)
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir
C. Stephan (2004)
An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
B. Gazzard (2003)
A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects
B. Gruzdev (2003)
Adverse effects of antiretroviral therapy
A. Carr (2000)
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial
F. Maggiolo (2004)
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
J. Gallant (2005)
Antiretroviral-drug resistance among patients recently infected with HIV.
S. Little (2002)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar